GSK Bags UK Approval for Exdensur as Asthma, Chronic Rhinosinusitis Treatment

11:29 PM EST, 12/15/2025 (MT Newswires) -- UK's Medicines and Healthcare products Regulatory Agency approved GSK's (GSK.L) Exdensur, or depemokimab, as an add-on treatment for asthma in patients 12 years old or older and for severe chronic rhinosinusitis in adults. The British drugmaker formally received marketing authorization on Monday, according to a same-day release. The medicine will be injected once every six months under the skin. The regulator noted that the medication is recommended for patients with uncontrollable symptoms despite standard-of-care-treatment.